A STOCHASTIC ECONOMIC EVALUATION OF LETROZOLE VERSUS TAMOXIFEN AS A FIRST-LINE HORMONAL THERAPY FOR ADVANCED BREAST CANCER IN POSTMENOPAUSAL PATIENTS IN GERMANY
ECONOMIC EVALUATION OF NEW POLY-CHEMOTHERAPY REGIMENS AS ALTERNATIVES TO CISPLATIN PLUS PACLITAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER
IMMUNOTHERAPY WITH AUTOLOGOUS TUMOR CELL-BCG VACCINE (ONCOVAX®) IN PATIENTS WITH STAGE II COLON CANCER
COST-EFFECTIVENESS OF FONDAPARINUX VS ENOXAPARIN AS PROPHYLAXIS AGAINST VENOUS THROMBOEMBOLISM FOLLOWING ORTHOPAEDIC SURGERY
ESTIMATION OF EXPENDITURES FOR CORONARY HEART DISEASE (CHD) IN GERMANY
MULTI-COUNTRY COMPARISON OF HYPERTENSION COSTS FROM HOSPITALIZATIONS AND AMBULATORY CARE
A BAYESIAN APPROACH TO NET HEALTH BENEFITS
COST-EFFECTIVENESS (CE) OF SCREENING DONATED BLOOD WITH MINIPOOL NUCLEIC ACID TESTING (NAT) FOR HEPATITIS B VIRUS (HBV), HEPATITIS C VIRUS (HCV), AND HUMAN IMMUNODEFICIENCY VIRUS (HIV)
METHODS FOR ASSESSING COSTS AND EFFECTS OF ANTIRETROVIRAL THERAPIES IN HIV
NHP AND 15D PERFORM WELL IN ASSESSMENT OF THE HRQOL OF HEALTHY WOMEN WITH HORMONE REPLACEMENT THERAPY
PRE-TERM PREGNANCY TERMINATIONS FOLLOWING EXPOSURE TO ANTIDEPRESSANTS
PATIENT PREFERENCE AND WILLINGNESS-TO-PAY IN FIVE EUROPEAN COUNTRIES FOR HUMALOG MIX25 COMPARED TO HUMULIN 30/70 FOR THE TREATMENT OF TYPE 2 DIABETES
THE EQUITY-EFFICIENCY TRADEOFF
MEASURING HEALTH IMPACTS ON WORK PERFORMANCE
VALIDATING A DISEASE MODEL ACCORDING TO CRITERIA OF EVIDENCE BASED MEDICINE
EFFICIENT PRODUCTION OF HEALTH BENEFITS
HEALTH ECONOMIC EDUCATION IN ALLOCATION DECISIONS
A RISK-ADJUSTED LEAGUE TABLE OF EXPECTED RETURNS
CROSS-CULTURAL DIFFERENCES IN NONADHERENT ATTITUDES
THE IMPACT OF VARYING DEGREES OF COMPLIANCE WITH OSTEOPOROSIS MEDICATION ON FRACTURE RATES IN ACTUAL PRACTICE
CLAIMS BASED MEASURES OF DRUG TAKING COMPLIANCE AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA
36 INTO I DOESN'T GO
THE TRANSFORMATION OF SOCIAL PREFERENCE WEIGHTS
ESTIMATING HEALTH UTILITY FROM A PHYSICAL FUNCTION ASSESSMENT IN RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH ADALIMUMAB (D2E7)
DISCOUNTING HEALTH BENEFITS
ECONOMIC EVALUATION OF A LARGE-SCALE MENINGOCOCCAL C VACCINATION PROGRAM IN THE NETHERLANDS
PRIMARY CARE PRESCRIBING AND ANTIBIOTIC RESISTANCE
DEVELOPMENT OF A FUNCTIONAL ASSESSMENT IN MIGRAINEURS MEASUREMENT TOOL BASED ON THE WHO'S ICIDH2 CLASSIFICATION
A COST-EFFECTIVENESS ANALYSIS OF ORAL TRIPTAN THERAPIES
PROJECTIONS FOR COPD IN THE NETHERLANDS
THE COST-EFFECTIVENESS OF RALOXIFENE COMPARED WITH NO DRUG THERAPY FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES WHEN HRT IS INAPPROPRIATE
LONG-ACTING RISPERIDONE IN SCHIZOPHRENIC PATIENTS COMPARED WITH ORAL OLANZAPINE AND HALOPERIDOL DECANOATE
STOCHASTIC COST-EFFECTIVENESS ANALYSIS OF CHRONIC VENOUS LEG ULCERS—THE CASE OF PROMOGRAN® IN A SWEDISH HEALTH CARE SETTING
COST-EFFECTIVENESS AND BUDGET IMPACT OF THE SIROLIMUS-ELUTING STENT IN THE STENT ERA
COST-EFFECTIVENESS OF LEUKODEPLETION IN MAJOR CARDIAC SURGERY
ECONOMIES OF SCALE IN INTENSIVE CARE UNITS
CHANGES IN COST-EFFECTIVENESS OVER TIME
SHOULD THE EUROQOL DESCRIPTIVE SYSTEM BE EXTENDED FROM THREE TO FIVE LEVELS? A METHODOLOGICAL STRATEGY WITH AN EMPIRICAL PILOT
WHAT IS “TIME” IN TIME PREFERENCE STUDIES?
LITERATURE REVIEW OF GUIDELINES FOR CROSS-CULTURAL ADAPTATION OF HRQL MEASURES
RECOMMENDATIONS ON HRQL/UTILITY DATA IN 14 EUROPEAN PHARMACOECONOMIC GUIDELINES
MEASURING POPULATION HEALTH FOR 191 COUNTRIES
PATIENT-DERIVED UTILITY ESTMATES OF CHRONIC HEPATITIS C BASED ON EQ-5D AND RS SCORES
COMPARISON OF THE SF6D AND THE EQ5D IN PATIENTS REQUIRING CORONARY REVASCULARISATION
IMPROVEMENT IN HEALTH UTILITY AMONG RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH ADALIMUMAB (D2E7), A FULLY HUMAN ANTI-TNF MONOCLONAL ANTIBODY
WILLINGNESS TO PAY FOR PHARMACIST-PROVIDED MENOPAUSE AND HORMONE REPLACEMENT THERAPY CONSULTATIONS
ESTIMATING WILLINGNESS TO PAY FOR DRUGS TO TREAT ADHD—A CONTINGENT VALUATION STUDY IN STUDENTS
WILLINGNESS TO PAY FOR A PHARMACIST INTERVENTION PROGRAM AMONG NONCOMPLIANT DYSLIPIDEMIA PATIENTS
ASSESSMENT OF PROPOSED GUIDELINES FOR PHARMACOECONOMIC SUBMISSIONS IN GREECE
VARIABILITY IN EUROPEAN REIMBURSEMENT SCHEMES FOR ANTIBIOTICS
IMPROVING PATIENT ACCESS TO INNOVATION—THE NEW BELGIAN REIMBURSEMENT PROCEDURE
OUT-OF-POCKET PAYMENT IN BELGIUM
“AUT IDEM”—250 MILLION € SAVINGS P. A. FOR STATUARY HEALTH INSURANCE IN GERMANY?
DRUG COSTS REGULATION SYSTEM IN THE SLOVAK REPUBLIC
MODELLING, ECONOMIC EVALUATIONS, AND THE DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES
AN ECONOMIC MODEL FOR COOPERATION BETWEEN A NOT-FOR-PROFIT HMO AND A PHARMACEUTICAL COMPANY IN A DISEASE MANAGEMENT PROGRAM: TRANSFORMING CONFLICT OF INTERESTS INTO UTILITY MAXIMIZATION
RISK SHARING IN A STATE FUNDED HEALTH SERVICE
ISPOR FIFTH ANNUAL EUROPEAN CONGRESS CONTRIBUTED PRESENTATION ABSTRACTS
DESCRIPTIVE AND COMPARATIVE STUDY OF PATIENT-MANAGEMENT BY HOMEOPATHIC GPS VERSUS ALLOPATHIC GPS
SELF-REPORTED PATIENT EXPERIENCE DATA, PROVIDED TO PHYSICIANS AT THE POINT-OF-CARE, OFFERS AN IMPORTANT COMPLEMENT TO TRADITIONAL EFFICACY DATA AND ENABLES THE DERIVATION OF PRACTICEWIDE TREATMENT GUIDELINES
INFLUENCING PRESCRIBING IN ENGLISH PRIMARY CARE
MANAGING THERAPEUTICS NOVELTIES USING A SCIENTIFIC EVIDENCE-BASED METHOD
THE USE OF PATHOLOGY-RELATED PARAMETERS IN EXPLAINING THE VARIATION OF PUBLIC EXPENDITURES ON MEDICAL IMAGING
GENERIC DRUG PRICES ARE TYPICALLY HIGHER IN CANADA THAN IN THE UNITED STATES
SPANISH NATIONAL HEALTH SERVICE (NHS)
ESTIMATING THE ECONOMIC BURDEN OF HOSPITALIZATION DUE TO PATIENT NONADHERENCE IN CANADA
HEALTH EXPENDITURE FOR THE DURATION OF LAST YEAR OF LIFE IN TAIWAN
HARMONIZATION OF HOSPITAL COSTS
ISPOR FIFTH ANNUAL EUROPEAN CONGRESS CONTRIBUTED PRESENTATION ABSTRACTS
WEBSITES AS TOOLS OF PROMOTING HEALTH IN SOUTH EAST EUROPE
THE CONTRIBUTION OF HEALTH ECONOMICS TO PORTFOLIO MANAGEMENT DECISIONS
USE OF POLICY MODELING TO PROMOTE INFORMED DECISION MAKING
METHODOLOGICAL ISSUES
CLASSIFICATION AND REGRESSION TREES HELP IN DEVELOPING EMBEDDED EVIDENCE-AND CONSENSUS-BASED GUIDELINES
HEALTH STATE VALUATIONS IN SUMMARY MEASURES OF POPULATION HEALTH
ECONOMIC STUDY OF MALNUTRITION IN ELDERLY PATIENTS LIVING IN THE COMMUNITY
PHARMACOECONOMIC ANALISIS OF THE TREATMENT WITH LEFLUNOMIDE-METHOTREXATE OR INFLIXIMAB-METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS RESISTANT TO METHOTREXATE
THE COST-EFFECTIVENESS ANALYSIS OF CELECOXIB AND NSAIDS WITH GASTROPROTECTIVE AGENTS FOR TREATMENT OF RHEUMATOID ARTHRITIS IN UKRAINE
VARIATION IN RESOURCE UTILIZATION AND TREATMENT COSTS FOR RHEUMATOID ARTHRITIS (RA) ACROSS 5 COUNTRIES IN AN ADALIMUMAB (D2E7) CLINICAL TRIAL
ISPOR FIFTH ANNUAL EUROPEAN CONGRESS CONTRIBUTED PRESENTATION ABSTRACTS
DISEASE SEVERITY AND COSTS AMONG PATIENTS STARTING A TREATMENT WITH COX-2 SPECIFIC INHIBITORS VERSUS NSAIDS PATIENTS IN ITALY
ANALYSIS OF CONSUMPTION OF NONSTEROID ANTIINFLAMMATORY DRUGS (GROUP M01) AT NATIONAL LEVEL IN DDD/1000/DAY
MODELLED COST-EFFECTIVENESS AND COSTUTILITY ANALYSIS OF VARIOUS TREATMENT STRATEGIES IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN IN POLAND
AN ECONOMIC EVALUATION OF CLOPIDOGREL IN SECONDARY PREVENTION OF ISCHEMIC EVENTS
PHYSICIAN CHARACTERISTICS OF THE NAVIGATOR TRIAL PREDICT AVERAGE LENGTH OF STAY (ALOS) IN ACUTE CORONARY SYNDROME (ACS)
ISPOR FIFTH ANNUAL EUROPEAN CONGRESS CONTRIBUTED PRESENTATION ABSTRACTS
COST-EFFECTIVENESS ANALYSIS OF N-3 POLYUNSATURED FATTY ACIDS (PUFA) AFTER MYOCARDIAL INFARCTION, FRENCH ASSESSMENT
COST IMPACT OF AMLODIPINE IN BRITISH COLUMBIA BASED ON THE PREVENT TRIAL RESULTS
THE COST COMPARISON OF CARDIOVERSION AND ANTIARRHYTHMIC THERAPY IN NONVALVULAR CHRONIC ATRIAL FIBRILLATION
ECONOMIC EVALUATION OF THE ATORVASTATIN VERSUS REVASCULARIZATION TREATMENT STUDY (AVERT)
ECONOMIC EVALUATION OF THE CORONARY ANGIOPLASTY AMLODIPINE RESTENOSIS STUDY (CAPARES)
OUTCOMES AND COSTS OF THROMBOPROPHYLAXIS WITH LOWMOLECULAR WEIGHT HEPARIN IN ACUTELYILL MEDICAL INPATIENTS
COST OF UNCONTROLLED HYPERTENSION IN CANADA
RESOURCE UTILIZATION DURING THE FOUR MONTHS FOLLOWING A DIAGNOSIS OF DEEP VENOUS THROMBOSIS
COST-EFFECTIVENES OF ENOXAPARIN AS THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS IN BRAZIL
COST OF MANAGING UNSTABLE ANGINA PATIENTS OVER A NINE-MONTH PERIOD
ECONOMIC EVALUATION OF A COMPLIANCE PROGRAM IN PATIENTS WITH STATIN THERAPY—DESIGN AND PILOT PHASE OF THE ORBITAL STUDY
MANAGEMENT EFFECTIVENESS AND COST/UTILITY RATIO IN CHRONIC HEART FAILURE
INCIDENCE AND ECONOMIC BURDEN OF DEEP VEIN THROMBOSIS AFTER TOTAL HIP REPLACEMENT IN HONG KONG
COST-EFFECTIVENESS ANALYSIS OF TREATMENTS TO REDUCE CHOLESTEROL CONCENTRATION, BLOOD PRESSURE AND SMOKING FOR THE PREVENTION OF CORONARY HEART DISEASE
SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH CRATAEGUS EXTRACT WS® 1442—TWO-YEAR-RESULTS OF A PROSPECTIVE PHARMACOECONOMIC STUDY
TWO METHODS OF ASSESSING COSTS OF PHARMACOLOGICAL TREATMENT ASSOCIATED WITH CHRONIC VENOUS INSUFFICIENCY (CVI) IN POLAND
A COST EFFECTIVENESS ANALYSIS OF SPIRONOLACTONE IN THE MANAGEMENT OF PATIENTS WITH SEVERE CHRONIC HEART FAILURE (CHF) IN THE IRISH HEALTHCARE SETTING
ECONOMIC EVALUATION OF THE PROSPECTIVE RANDOMIZED EVALUATION OF VASCULAR EFFECT OF NORVASC STUDY (PREVENT)
A PHARMACOECONOMIC EVALUATION OF AGGRESSIVE LIPID-LOWERING THERAPY COMPARED WITH ANGIOPLASTY IN STABLE CORONARY ARTERY DISEASE IN SPAIN
PHARMACOECONOMIC COMPARISON OF THE ANTIHYPERTENSIVE TREATMENT WITH TWO DIFFERENT ANGIOTENSINE CONVERTING ENZYME INHIBITORS
COST-EFFECTIVENSS OF ANTICOAGULATION MANAGEMENT IN TWO MODELS OF CARE
ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CVD EVENTS WITH ATORVASTATIN
THE HEALTH ECONOMIC IMPLICATIONS OF TREATING ANEMIA IN PATIENTS WITH CONGESTIVE HEART FAILURE
COMPARING RESOURCE USE INTENSITY IN THREE POPULATIONS WITH ATHEROTHROMBOSIS
PERSISTENCE WITH ANTIHYPERTENSIVE DRUG TREATMENT
THE COST-EFFECTIVENESS OF DIAGNOSTIC STRATEGIES WITH ANGIOGRAPHY AND/OR DUPLEX SCANNING FOR AORTOILIAC AND FEMOROPOPLITEAL ARTERIAL DISEASE
PROBABILISTIC SENSITIVITY ANALYSIS FOR EVALUATING COST-EFFECTIVENESS IN SECONDARY PREVENTION OF ISCHEMIC EVENTS
ACCEPTANCE AND RELIABILITY OF A COST-MEASUREMENT QUESTIONNAIRE IN CARDIAC REHABILITATION
THE USE OF STATINS IN SECONDARY CARE
COST-EFFECTIVENESS OF METHODS TO QUIT SMOKING IN FINNISH HEALTH CARE
COST-EFFECTIVENESS OF PATHOGEN INACTIVATION FOR PLATELET TRANSFUSIONS IN DUTCH CARDIAC SURGERY
COSTS OF STROKE
OBESITY AND POTENTIAL COST OFFSETS FROM WEIGHT LOSS—FINDINGS FROM THE SWEDISH MALMO PREVENTION STUDY
DOES COMPLIANCE WITH ACE-I, DIGOXIN AND SPIRONOLACTONE INFLUENCE THE TIME TO EVENT IN PATIENTS WITH HEART FAILURE?
LIPID LOWERING MEDICATIONS FOLLOWING CORONARY REVASCULARIZATION PROCEDURES
A REVIEW OF THE PHARMACOTHERAPEUTIC MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION
COMORBIDITIES CAUSING INCREASING MORTALITY AT AGES UNDER 65 IN CARDIOVASCULAR DISEASE AND HYPERTENSION
SCREENING FOR ANEURYSMS AFTER SUCCESSFUL TREATMENT FOR SUBARACHNOID HAEMORRHAGE
UNCERTAINTIES IN COST-EFFECTIVENESS EVALUATION OF CAROTID ANGIOPLASTY AND STENTING
IS THERE ANY RELATIONSHIP BETWEEN COMPLIANCE AND HRQOL IN PATIENTS WITH HEART FAILURE?
THE IMPACT OF AN EDUCATIONAL INTERVENTION ON MULTIPLE HEALTH REALTED QUALITY OF LIFE MEASURES IN PATIENTS WITH HEART FAILURE (HF)
DETERMINANTS OF FIRST-YEAR QUALITY OF LIFE (QOL) AFTER SURGERY—INTERIM ANALYSIS OF A RANDOMISED TRIAL WITH LAPBAND-SURGERY AND VERTICAL BANDED GASTROPLASTY (VBG)
CORRELATES OF SATISFACTION WITH PAIN CONTROL AMONG CARDIOVASCULAR PATIENTS IN THE US (2001)
THE ASSESSMENT OF THE INFLUENCE OF AN EDUCATIONAL INTERVENTION ON PATIENT IMPORTANT OUTCOMES INCLUDING HEALTH RELATED QUALITY OF LIFE (HRQOL) AND MORTALITY USING A TIME-TO-EVENT SURVIVAL ANALYSIS IN PATIENTS WITH HEART FAILURE
WHAT IS THE WILLINGNESS TO PAY FOR FUTURE HEALTH BENEFITS AMONG HYPERTENSIVE PATIENTS—A PILOT STUDY IN POLISH SETTING
THE INFLUENCE OF COPAYMENTS ON THE DEMAND FOR DRUGS WITH THERAPEUTIC COMPETITORS
EVALUATION OF NITRATE PRESCRIPTION PATTERNS AMONG PHYSICIANS FROM DIFFERENT SPECIALITIES IN ISRAEL
POSSIBILITIES OF NEW TECHNOLOGIES AMONG PATIENTS WITH HYPERTENSION
LOW LEVEL OF CONSISTENCY BETWEEN QUALITATIVE (NCEP-II) AND QUANTITATIVE METHODS TO RECOMMEND PHARMACEUTICAL TREATMENT OF HYPERCHOLESTEROLEMIA IN INDIVIDUALS WITHOUT CORONARY HEART DISEASE
INFLUENCE OF THREE HYPERTENSION GUIDELINES ON RATES OF TREATMENT INDICATION
SMOKING CESSATION
SMOKING DEPENDENCY
ALLOCATION OF RESOURCES BETWEEN SMOKING CESSATION METHODS AND PHARMACEUTICAL TREATMENT OF HYPERCHOLESTEROLEMIA BASED ON COST-EFFECTIVENESS AND THE SOCIAL WELFARE FUNCTION
IMPLICATIONS OF TREATMENT GUIDELINES
RANDOMIZED CONTROLLED INTERVENTION IN CARDIOVASCULAR DRUG TREATMENT IN NURSING HOMES
EMPLOYMENT LOSSES RELATED TO INFLAMMATORY BOWEL DISEASE IN THE UNITED STATES
ECONOMIC BURDEN OF IBS
HEALTH CARE RESOURCE UTILIZATION AND COSTS OF TREATING NSAID-ASSOCIATED GASTROINTESTINAL TOXICITY IN JAPAN
LOW-DOSE PPI AND STANDARD-DOSE PPI COMPARED WITH H2RA FOR MAINTENANCE THERAPY OF GERD—A COST-EFFECTIVENESS ANALYSIS USING MARKOV MODEL
A COST-EFFECTIVENESS ANALYSIS OF ESOMEPRAZOLE VS. OMEPRAZOLE IN THE ACUTE TREATMENT OF PATIENTS WITH REFLUX OESOPHAGITIS IN GREECE
COST COMPARISON OF ESOMEPRAZOLE BASED AND OMEPRAZOLE BASED HELICOBACTER PYLORI ERADICATION STRATEGIES IN DUODENAL ULCER DISEASE IN GREECE
ANALYSIS OF RESOURCE USE AND COSTS ASSOCIATED WITH MINOR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAID) RELATED GASTRO-INTESTINAL (GI) EVENTS
META-ANALYSIS OF ESOMEPRAZOLE 40MG AND LANSOPRAZOLE 30MG IN THE HEALING OF REFLUX OESOPHAGITIS
OUTCOMES ANALYSIS OF RABEPRAZOLE (ACIPHEX) USE AT A VETERAN AFFAIRS MEDICAL CENTER
TOWARDS A MULTISTAGE DECISION ANALYSIS FOR THE TREATMENT OF FAECAL INCONTINENCE
IMPACT OF IBS ON QUALITY OF LIFE AND PSYCHOLOGICAL WELL-BEING IN PATIENTS AND RELATIVES
IRRITABLE BOWEL SYNDROME (IBS) SIGNIFICANTLY AFFECTS PATIENT QUALITY OF LIFE (QOL) AND IS RESPONSIBLE FOR HIGH COSTS IN FRANCE
HEALTH STATE UTILITIES AND WILLINGNESS TO PAY IN GERD PATIENTS WITH HEARTBURN
CORRELATION BETWEEN DIFFERENT PRODUCTIVITY VARIABLES OBTAINED FROM THE WPAI-GERD QUESTIONNAIRE
FORMULARY CONVERSION OF PROTON PUMP INHIBITORS
EVALUATION OF THE USE OF PROTON PUMP INHIBITORS IN A PUBLIC HOSPITAL IN HONG KONG
CHOLINESTERASE INHIBITORS REDUCE INSTITUTIONALIZATION RISK AND MAY REDUCE OVERALL ECONOMIC BURDEN FOR PATIENTS WITH DEMENTIA IN A NATURALISTIC TREATMENT SETTING
ECONOMIC IMPACT OF TREATMENT OF DEMENTIA FOR GERMANY—A PROGNOSIS TO 2050
SOCIO-ECONOMIC IMPACT OF CHRONIC DAILY HEADACHE IN THE GENERAL POPULATION IN FRANCE
SWITCHING AND PERSISTENCY IN A NSAID AND COX-2 SPECIFIC INHIBITOR USER POPULATION IN MANAGED CARE
DIRECT COSTS OF BACK PAIN IN THE UNITED STATES
THE BURDEN OF MIGRAINE
ECONOMIC EVALUATION OF LEVETIRACETAM AS ADJUNCTIVE THERAPY IN REFRACTORY EPILEPTIC PATIENTS
ADJUNCTIVE TOPIRAMATE THERAPY IN PATIENTS WITH REFRACTORY SEIZURES
RETROSPECTIVE EVALUATION OF DYSPORTTM AND BOTOXTM DRUG UTILIZATION IN THE MANAGEMENT OF PATIENTS WITH CERVICAL DYSTONIA OR BLEPHAROSPASM
ECONOMIC IMPACT OF GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS
USE OF THE TOPS AS A PAIN-SPECIFIC HRQOL INSTRUMENT
PHYSICIAN PREFERENCE FOR ANTIEPILEPTIC DRUG CONCENTRATION TESTING
QUALITY OF LIFE (QOL) AND PHARMACOECONOMICAL ASPECTS IN PATIENTS WITH SYMPTOMATIC LOCALIZATION-RELATED EPILEPSIES (SLE) IN MOSCOW
ISPOR FIFTH ANNUAL EUROPEAN CONGRESS CONTRIBUTED PRESENTATION ABSTRACTS
EVALUATION OF THE RELATIONSHIP BETWEEN EPILEPSY SEVERITY AND UTILITY
MEDICATION USE IN PATIENTS WITH LOW BACK PAIN
COMPLIANCE OF TWO TREATMENTS OF ALZHEIMER's DISEASE
FORMULARY DECISION SUPPORT FOR INTERFERON-BETA-IA USING ANALYSIS OF CARE-SEEKING BEHAVIOR FOR MULTIPLE SCLEROSIS
THE HEALTH CARE COSTS OF SCHIZOPHRENIA IN AUSTRALIA
ANTIPSYCHOTIC USE PATTERNS AND HEALTHCARE COSTS FOR INDIVIDUALS WITH SCHIZOPHRENIA TREATED WITH HALOPERIDOL, OLANZAPINE OR RISPERIDONE IN A MEDICAID POPULATION
A COST-EFFECTIVENESS COMPARISON OF OLANZAPINE AND RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA IN ITALY
ESTIMATING MEDICAL COST REDUCTION IN TREATING SCHIZOPHRENIA WITH CLOZAPINE
A DISCRETE EVENTS MODEL OF LONG-TERM OUTCOMES AND COST OF TREATMENT WITH LONG ACTING RISPERIDONE IN SCHIZOPHRENIA
DIRECT MEDICAL COSTS FOR TREATMENT OF PATIENTS EXPERIENCING BIPOLAR DISORDER EPISODES IN THE UK
BOTTOM-UP OR TOP-DOWN? IMPACT OF PATIENT SELECTION ON COST-OF-ILLNESS RESULTS
COST-EFFECTIVENESS OF MIRTAZAPINE COMPARED TO FLUOXETINE IN THE TREATMENT OF MODERATE AND SEVERE DEPRESSION IN HUNGARY
ESTIMATING COST-EFFECTIVENESS OF CONCERTA OROS IN ATTENTIONDEFICIT/HYPERACTIVITY DISORDER (ADHD)—ADAPTING THE CANADIAN COORDINATING OFFICE FOR HEALTH TECHNOLOGY ASSESSMENT's (CCOHTA) ECONOMIC MODEL OF METHYLPHENIDATE IMMEDIATE RELEASE VERSUS BEHAVIOURAL INTERVENTIONS FROM A PARENT's PERSPECTIVE
LENGTH OF STAY AND ANTIPSYCHOTIC TREATMENT COSTS OF PATIENTS WITH ACUTE PSYCHOSIS ADMITTED TO HOSPITAL
ANTIPSYCHOTIC MEDICATION PATTERNS IN SCHIZOPHRENIA OUTPATIENTS AND INPATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY
PATIENT AND DISEASE CHARACTERISTICS IN SCHIZOPHRENIA OUTPATIENTS AND INPATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY
STUDY DESCRIPTION AND BASELINE RESULTS OF THE SCHIZOPHRENIA OUTCOMES SURVEY (SOS) OBSERVATIONAL STUDY IN BELGIUM
INCIDENCE OF HYPERLIPIDEMIA DURING TREATMENT OF SCHIZOPHRENIA
SEXUAL DYSFUNCTION AND ANTIPSYCHOTIC DRUG ADHERENCE IN PEOPLE WITH SCHIZOPHRENIA
RECRUITMENT FOR SCHIZOPHRENIA RESEARCH
TREATMENT SATISFACTION AND COMPLIANCE WITH RISPERIDONE USE IN PATIENTS WITH BIPOLAR DISORDER
EVALUATION OF CLINICAL EFFICACY OF WEEKLY FLUOXETIN COMPARED WITH DAILY FLUOXETIN 40 MG IN AMBULATORY PATIENTS WITH MAJOR DEPRESSION
GENDER DIFFERENCES IN PSYCHOACTIVE MEDICATION TREATMENT FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (AD/HD)
THE EFFECTS OF ETHNICITY AND ANTIPSYCHOTIC AGENT ON MEDICATION ADHERENCE IN A MEDICAID POPULATION
IMPROVING THE MEASUREMENT PROPERTIES OF THE QUALITY OF LIFE IN DEPRESSION SCALE
ADHD HAS A SIGNIFICANT BURDEN UPON THE INDIVIDUAL, FAMILY AND SOCIETY IN EUROPE
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
THERE ARE SIGNIFICANT BARRIERS TO THE DIAGNOSIS AND TREATMENT OF ADHD IN EUROPE
CORRESPONDENCE COURSE FOR GPS IMPROVED QUALITY AND PERSISTENCY OF ANTI-DEPRESSIVE THERAPY (RESULTS FROM THE IMPROVE-D STUDY)
SIMULATING THE COURSE OF SCHIZOPHRENIA USING DISCRETE EVENTS MODELLING
INPATIENT AND OBSERVATION UNIT COSTS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
3329 STUDY TO EVALUATE HOSPITAL COSTS FOR ACUTE EXACERBATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN (EPOC-COST STUDY)
AN ANALYSIS OF THE LENGTH AND COSTS OF RESPIRATOR USE WITH OBSERVATIONAL DATA BASED ON MEDICAL RECORDS
INHALED ANTIINFLAMMATORY MEDICATION USE AND SUBSEQUENT HOSPITALIZATIONS AMONG TEXAS MEDICAID PATIENTS WITH PERSISTENT ASTHMA
EPIDEMIOLOGICAL STUDY ESTIMATING THE PREVALENCE OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS IN GERMANY
ASSESSMENT OF RESPIRATORY DISEASE SEVERITY USING POSTAL QUESTIONNAIRES
HEALTH RELATED QUALITY OF LIFE (HRQOL) IN ASTHMA PATIENTS IN RELATIONSHIP TO ASTHMA SEVERITY DEGREE
QUALITY OF LIFE AND COSTS FOR MODERATE AND SEVERE ASTHMA IN FRANCE
EVALUATION OF A DISEASE MANAGEMENT PROGRAM (DMP) FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN GERMANY
A DISEASE MANAGEMENT PROGRAM IN FRANCE
THE NEW METHOD FOR TIME ADJUSTMENT OF THE NUMBER NEEDED TO TREAT AND ITS APPLICATION TO PHARMACOECONOMICS ANALYSIS
THE USE OF DISCRETE CHOICE MODELLING IN THE DESIGN OF CLINICAL TRIALS
RELEVANCE OF PATIENT REPORTED OUTCOMES FOR CHRONIC PAIN PATIENTS
WHEN CAN MISSING DATA BE CONSIDERED MISSING AT RANDOM (MAR) IN SUBSTANCE ABUSE TREATMENT OUTCOMES RESEARCH?
VALUATION OF NEW DRUG APPLICATIONS OF PHARMACEUTICAL COMPANIES USING COMPOUND OPTION MODELS
MODIFYING COST-EFFECTIVENESS RATIOS TO BE MAXIMALLY COMPARABLE ACROSS MULTIPLE DISEASES
VALUATION OF INFORMAL CARE
TRENDS IN DATA SOURCES USED FOR ECONOMIC EVALUATION
BEHAVIOURAL ECONOMICS
ISPOR QUALITY OF LIFE SPECIAL INTEREST GROUP TRANSLATION AND CULTURAL ADAPTATION
A DALY IS A QALY—OR IS IT?
GENERIC VERSUS TREATMENT SPECIFIC TREATMENT SATISFACTION MEASUREMENT
THE RELEVANCE OF QUANTITY AND QUALITY OF LIFE-YEARS AFTER TREATMENT IN PRIORITIZING BETWEEN DIFFERENT PATIENTS
THE INFLUENCE OF ILLNESS EXPERIENCE ON HEALTH STATE VALUATIONS
THE INFLUENCE OF ILLNESS EXPERIENCE ON VALUATION COMPRESSION
ASSESSING QUALITY OF LIFE IN THE ELDERLY
ASSESSMENT OF QUALITY OF LIFE IN CHILDREN
THE INTERNATIONAL HEALTH-RELATED QUALITY OF LIFE OUTCOMES DATABASE (IQOD) PROGRAMME—WHQ AND PGWBI DATABASES
A CRITICAL REVIEW OF HEALTH-RELATED PRODUCTIVITY MEASURES
COST ANALYSIS OF HLA-IDENTICAL SIBLING AND VOLUNTARY UNRELATED ALLOGENEIC BONE MARROW AND PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ADULTS WITH ACUTE MYELOCYTIC LEUKAEMIA OR ACUTE LYMPHOBLASTIC LEUKAEMIA
COST-EFFECTIVENESS OF NEW CERVICAL CANCER SCREENING TECHNOLOGIES
ISPOR FIFTH ANNUAL EUROPEAN CONGRESS CONTRIBUTED PRESENTATION ABSTRACTS
ONCE-PER-CYCLE FIXED-DOSE ADMINISTRATION OF PEGFILGRASTIM REDUCED RESOURCE UTILIZATION AND COSTS COMPARED WITH DAILY FILGRASTIM IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA
COMPARING THE COST-EFFECTIVENESS OF FRONT-LOADED DARBEPOETIN ALFA WITH EPOETIN ALFA FOR ANEMIA MANAGEMENT IN CHEMOTHERAPY-TREATED CANCER PATIENTS IN UNITED STATES
ECONOMICAL EVALUATION OF RALTITREXED VERSUS FLUOROURACIL PLUS LEUCOVORIN (5-FU + LV) FOR TREATMENT OF ADVANCED COLORECTAL CANCER
MAJOR DETERMINANTS OF COST IN ADVANCED NON-SMALL-CELL LUNG CANCER CHEMOTHERAPY REGIMES IN FRANCE
AVERAGE TOTAL COST OF TREATING ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS IN SPAIN USING VARIOUS CHEMOTHERAPY DOUBLETS
COST-EFFICACY OF ZOLEDRONIC 4MG ACID VS. PAMIDRONATE 90MG IN THE TREATMENT OF HYPERCALCEMIA OF MALIGNACY (HCM)
COST ANALYSIS OF CAPECITABINE VERSUS 5-FU/LV FOR COLORECTAL CANCER PATIENTS IN THE NETHERLANDS
PROPENSITY ANALYSIS OF EPOETIN USE AND ITS IMPACT ON OVERALL COSTS OF CANCER CARE
IMPACT OF INNOVATIVE AND EXPENSIVE THERAPIES IN THE TREATMENT OF METASTATIC BREAST CANCER (MBC)
GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIALS (GREAT) IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER
IN THE UK GEMZAR DOUBLET HAS LOWEST TOTAL TREATMENT COSTS FOR NSCLC COMPARED TO FOUR OTHER CHEMOTHERAPY DOUBLETS
ANEMIA RESULTS IN INCREASED UTILIZATION IN CANCER PATIENTS
A COMPARISON OF THE COSTS OF GEMCITABINE/CISPLATIN AND GEMCITABINE/CARBOPLATIN COMBINATION REGIMENS IN THE TREATMENT OF ADVANCED NSCLC IN THE UK AND FRANCE
COMPARING THE COST-EFFECTIVENESS OF 3 MCG/KG Q2W DARBEPOETIN ALFA WITH STANDARD DOSE EPOETIN ALFA FOR ANEMIA MANAGEMENT IN CHEMOTHERAPY-TREATED CANCER PATIENTS IN UNITED STATES
DERIVING A UTILITY WEIGHTED INDEX FROM CONDITION-SPECIFIC MEASURES
EXAMINING PREFERENCES AND TIME-TRADE-OFF UTILITY FOR GEMCITABINE PLUS CISPLATIN IN THE TREATMENT OF BLADDER CANCER
IS THERE DIFFERENCE BETWEEN GEMCITABINE BASED NSCLC TREATMENT AND OTHER PLATINUM BASED COMBINATIONS FOR RESPONSE RATES AND TOXICITY?
CANCER CHEMOTHERAPY AT HOME
COST-EFFECTIVENESS OF SWITCHING PATIENTS TO COMBINED GLIBENCLAMIDE AND METFORMIN (GLUCOVANCE) WHEN POORLY CONTROLLED WITH METFORMIN MONOTHERAPY
COST-EFFECTIVENESS ANALYSIS OF GLYCEMIC CONTROL WITH PIOGLITAZONE HYDROCHLORIDE FOR JAPANESE PATIENTS WITH TYPE II DIABETES
INTENSIVE LIFESTYLE CHANGES OR METFORMIN IN OVERWEIGHT, GLUCOSE INTOLERANT PATIENTS
THE HEALTH-ECONOMIC IMPLICATIONS OF THE “IRBESARTAN IN DIABETIC NEPHROPATHY TRIAL” (IDNT) IN FRANCE AND BELGIUM
LONG-TERM CONSEQUENCES FOR THE TREATMENT OF HYPERTENSIVE DIABETES TYPE 2 PATIENTS WITH A FIXED COMBINATION OF AN ACE-INHIBITOR AND NON-DIHYDROPYRIDINE-CALCIUM-CHANNEL-BLOCKER IN COMPARISON TO OTHER COMBINATION THERAPIES
RETROSPECTIVE STUDY EVALUATING CLINICAL AND ECONOMIC OUTCOMES OF MONOTHERAPY VERSUS DUAL THERAPY IN DIABETIC PATIENTS IN A COUNTY HEALTH CARE SYSTEM
THE WHO/IDF CARECARD DIABETES AS AN INTERNET-BASED APPROACH FOR QUALITY ASSURANCE IN SWITZERLAND
TYPE-2 DIABETES AND BODY MASS INDEX (BMI)
DEVELOPMENT AND VALIDATION OF THE INSULIN TREATMENT SATISFACTION QUESTIONNAIRE (ITSQ)
A CROSS-OVER RANDOMISED CONTROLLED TRIAL TO COMPARE PSYCHOLOGICAL BARRIERS TO INSULIN SELF-INJECTION WITH THE INNOLET AND VIAL/SYRINGE
TYPE I DIABETES, LONG-TERM COMPLICATIONS AND QUALITY OF LIFE MEASURED WITH RAND-36 HEALTH PROFILE MEASURE
SELF-ASSESSMENT OF DIABETES CONTROL
REAL WORLD ADHERENCE BENEFITS FROM COMBINATION PRODUCTS UTILIZED IN DIABETICS
MEDICAID MANAGED CARE QUALITY AMONG BLACK AND WHITE ADULTS WITH DIABETES MELLITUS
USE OF THE PATIENT ANALYSIS & TRACKING SYSTEM (PATS) IN ASSESSMENT OF RATIONAL PHARMACOTHERAPY OF DIABETICS IN A BIG HOSPITAL
COST OF ILLNESS OF GLAUCOMA IN CANADA
MEDICAL PREDICTIVE FACTORS OF GLAUCOMA TREATMENT COSTS IN FRANCE
LIFE-LONG SOCIETAL NET VALUE OF GLAUCOMA TREATMENT
A DISEASE SEVERITY STAGING SYSTEM FOR MEASURING THE COST OF GLAUCOMA PROGRESSION IN EUROPE
COST-UTILITY ANALYSIS OF TIMOLOL VERSUS LATANOPROST VERSUS TRAVOPROST IN THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION
PATIENT REPORTED OUTCOMES AND HEATH SYSTEM ECONOMIC IMPACT OF A REFORMULATION TO IMPROVE BRIMONIDINE 0.2% PATIENT OUTCOMES
COST-UTILITY OF VITAMINS FOR THE TREATMENT OF MACULAR DEGENERATION
LOW VISUAL ACUITY AND BLINDNESS SOCIAL COSTS IN FRANCE
COST-EFFECTIVENESS AND COST-UTILITY OF OLOPATADINE IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS (SAC) IN 6 EUROPEAN COUNTRIES
PHARMACOECONOMIC EVALUATION OF A NEW TWO COMPOUND OINTMENT (DAIVOBET®) AND CALCIPOTRIOL (DAIVONEX®) IN THE TREATMENT OF PSORIASIS VULGARIS IN SWEDEN
ECONOMIC EVALUATION OF METHOTREXATE AND CYCLOSPORIN A FOR PATIENTS WITH SEVERE PSORIASIS
BURDEN OF ATOPIC DERMATITIS IN SWITZERLAND
RESOURCE UTILIZATION IN PATIENTS SUFFERING FROM ATOPIC DERMATITIS IN GERMANY
COST EFFECTIVENESS OF PIMECROLIMUS (ELIDEL) IN THE TREATMENT OF CHILDREN WITH ATOPIC DERMATITIS
USING A DISCRIMINANT FUNCTION TO MODEL THE LONG-TERM VISUAL FIELD CONSEQUENCES OF IOP CONTROL
MEDICAL OUTCOME OF GLAUCOMA TREATMENT IN FRANCE
PSORIASIS AND DEPRESSIVE SYMPTOMATOLOGY
VISION RELATED QUALITY OF LIFE OF FRENCH PATIENTS IS AFFECTED BY TOPICAL GLAUCOMA TREATMENT SIDE EFFECTS
INITIAL DEVELOPMENT AND VALIDATION OF THE EYE ALLERGY PATIENT IMPACT QUESTIONNAIRE (EAPIQ)
DERIVATION OF SYMPTOMS SCORES AND QOL SCORES FROM CLINICAL DATA IN SEASONAL ALLERGIC CONJUNCTIVITIS
IMPACT OF HYDROTHERAPY CARES ON THE QUALITY OF LIFE OF PATIENTS' SUFFERING FROM SKIN DISEASES
IMPACT OF CHILDREN's SKIN DISEASES ON THEIR PARENTS' QUALITY OF LIFE
PSORIASIS AND QUALITY OF LIFE SPANISH RESULTS
PSORIASIS, QUALITY OF LIFE AND DEPRESSIVE SYMPTOMATOLOGY
ASSESSMENT OF THE DERMATOLOGIC LIFE QUALITY INDEX (DLQI) IN CHRONIC IDIOPATHIC URTICARIA
HEALTH STATE UTILITIES IN PATIENTS WITH DERMATOLOGICAL PROBLEMS—A POPULATION STUDY
THE COSTS OF SEVERE SEPSIS—THE NETHERLANDS, 2000
SEVERE SEPSIS
THE TREATMENT OF SEPSIS PATIENTS WITH DROTRECOGIN ALFA (ACTIVATED)
COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) IN THE TREATMENT OF SEVERE SEPSIS IN SPAIN
COST-EFFECTIVENESS OF DROTRECOGIN ALFA (ACTIVATED) FOR THE TREATMENT OF SEVERE SEPSIS
COST-EFFECTIVENESS ANALYSIS OF LINEZOLID VERSUS TEICOPLANIN IN THE TREATMENT OF INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA IN SPAIN
OUTCOMES AND PATIENT CHARACTERISTICS ASSOCIATED WITH SYSTEMIC FUNGAL INFECTIONS
LENGTH OF STAY AND ANTIFUNGAL TREATMENTS COSTS IN PATIENTS WITH SYSTEMIC MYCOSIS
PHARMACOECONOMIC ANALYSIS OF COMMUNITY ACQUIRED PNEUMONIA TREATMENT WITH TELITHROMYCIN OR CLARITHROMYCIN
ECONOMIC EVALUATION DEMONSTRATES THAT MOXIFLOXACIN IV/PO MONOTHERAPY IS COST-EFFECTIVE TO THE SPANISH NATIONAL HEALTHCARE SYSTEM WHEN COMPARED TO IV/PO AMOXICILLIN/ CLAVULANATE ± CLARITHROMYCIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
COMPARING HOSPITAL COSTS BETWEEN LINEZOLID AND VANCOMYCIN IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCAL SPECIES (MRSS) INFECTIONS
PHARMACOECONOMIC ANALYSIS OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS TREATMENT WITH TELITHROMYCIN OR CEFUROXIME-AXETIL
FIVE-YEAR BUDGET IMPACT AND LIFETIME COST EFFECTIVENESS OF A LOPINAVIR/RITONAVIR (LVP/r) VS. A NELFINAVIR (NFV) CONTAINING REGIMEN FOR TREATMENT-NAïVE PATIENTS
COST-CONSEQUENCE COMPARISON OF LOPINAVIR/RITONAVIR (LPV/r) VS. NELFINAVIR (NFV) THERAPY IN TREATING ANTIRETROVIRAL NAÏVE HIV PATIENTS USING CLINICAL TRIAL DATA
ECONOMIC BURDEN OF CHRONIC HEPATITIS B VIRUS INFECTION AND POTENTIAL COST SAVINGS WITH LAMIVUDINE
INFLUENZA TREATMENT WITH OSELTAMIVIR IN A HIGH RISK POPULATION—A COSTEFFECTIVE OPTION FOR THE HEALTH CARE PAYER
COST-EFFECTIVENESS OF 23-VALENT ANTIPNEUMOCOCCICAL VACCINATION IN CATALONIA (SPAIN)
RELEVANCE OF COMPLICATIONS AS COST DRIVERS OF VARICELLA
COST BENEFIT ANALYSIS ON VACCINATION FOR MEASLES IN JAPAN
THE COST-EFFECTIVENESS OF ANTIRETROVIRAL REGIMENS CONTAINING PROTEASE INHIBITORS (PIS) OR NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI) IN THE TREATMENT OF HIV-INFACTED INDIVIDUALS IN POLAND
HOSPITALISATION COSTS FOR YOUNG CHILDREN WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION
PHARMACOECONOMIC EVALUATION OF STREPTOMYCIN VERSUS ETHAMBUTOL AS PRIMARY ANTITUBERCULAR DRUGS IN LAGOS UNIVERSITY TEACHING HOSPITAL
PHARMACOECONOMIC EVALUATION OF ANTIBACTERIALS UTILIZATION IN PRIMARY, SECONDARY AND TERTIARY HOSPITALS IN DEVELOPING ECONOMY
IMPACT OF INFLUENZA VACCINATION ON WORK PRODUCTIVITY IN A COLOMBIAN COMPANY
VACCINATION IN HEALTHY WORKING ADULTS
THE COST EFFECTIVENESS OF SAFE AND APPROPRIATE USE OF INJECTION POLICIES IN HEALTH CARE SETTINGS
IMPACT OF SIMPLER HIV-THERAPY ON ADHERENCE AND QUALITY OF LIFE
REVIEW OF QOL AND HRQOL INSTRUMENTS AVAILABLE FOR MEASURING OUTCOME IN HIV/AIDS
PSYCHOMETRIC PROPERTIES OF THE MODIFIED VIH-47 IN A THERAPEUTIC TRIAL EVALUATING THE IMPACT OF AN EDUCATIONAL PROGRAM IN HIV + PATIENTS
FURTHER DEVELOPMENT OF THE INFLUENZA DAILY DISRUPTION QUESTIONNAIRE
INVESTIGATION INTO THE FEASIBILITY OF DERIVING RELATIVE AND ABSOLUTE UTILITY FROM THE RECURRENT GENITAL HERPES QUALITY OF LIFE QUESTIONNAIRE (RGHQOL)
A COMPARISON OF CONJOINT ANALYSIS AND TIME TRADE OFF ELICITED UTILITIES FOR QUALITY OF LIFE STATES ASSOCIATED WITH THE TREATMENT OF GENITAL HERPES
FACTORS INFLUENCING INAPPROPRIATE ANTIBIOTIC PRESCRIBING FOR CHILDREN WITH ACUTE BRONCHITIS IN AMBULATORY CARE SETTING
INITIAL ANTIVIRAL TREATMENT OF CHRONIC HEPATITIS C
VARICELLA VACCINATION OF PRE-SCHOOL CHILDREN
INCIDENCE OF SEVERE SEPSIS IN THE NETHERLANDS
A COMPREHENSIVE NATURAL HISTORY MODEL OF HUMAN PAPILLOMAVIRUS (HPV) INFECTION AND CERVICAL CANCER
AN ECONOMIC EVALUATION OF NOVOSEVEN IN THE MANAGEMENT OF HAEMOPHILIA PATIENTS WITH INHIBITORS IN SLOVAKIA
DEVELOPMENT OF ECONOMIC AND OUTCOMES MODEL OF HEMOPHILIA TREATMENT IN LATIN AMERICA AND SOUTH EAST ASIA
JOINT RECOVERY IN HIP AND KNEE REPLACEMENT
INCIDENCE AND PREVENTION OF NEEDLE STICK INJURY RELATED TO SUBCUTANEOUS INJECTION
EVALUATION OF A PALLIATIVE CARE TEAM ON RESOURCE UTILIZATION IN AN ACUTE CARE SETTING
ELECTRONIC IMPLEMENTION OF AN APPROVED TABLET SPLITTING GUIDE WITH PROVIDER ORDER ENTRY—ASSOCIATED COST SAVINGS
THE IMPACT OF FALLING ON HEALTH CARE UTILIZATION AND COSTS
THE COST-EFFECTIVENESS OF OSTEOGENIC PROTEIN I IN THE TREATMENT OF TIBIAL NONUNIONS IN THE UK AND GERMANY
A PHARMACOECONOMIC EVALUATION OF THE USE OF THYROTROPIN-ALFA (THYROGEN®) IN THE DETECTION OF THYROID REMNANTS AND WELL-DIFFERENTIATED THYROID CANCER IN THE DUTCH HEALTH CARE SETTING
IMPROVEMENT IN QUALITY OF LIFE IN GROWTH HORMONE (GH) REPLACED HYPOPITUITARY ADULTS WITH GH DEFICIENCY IS CORRELATED WITH PATIENT-REPORTED OUTCOMES
ASSESSING PROVIDER TIME FOR ANAEMIA MANAGEMENT OF DIALYSIS PATIENTS USING TIME & MOTION METHODS
COSTS OF CHRONIC KIDNEY DISEASE (CKD)
BRANDED VS GENERIC CYCLOSPORINE IN DE-NOVO KIDNEY TRANSPLANTATION—WHERE ARE THE COST SAVINGS?
AN ECONOMIC MODEL OF UNSTABLE BLADDER IN BELGIUM
A STRAIGHTFORWARD COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING TREATMENTS FOR OVERACTIVE BLADDER
EVALUATING THE COST OF LONG-ACTING TREATMENTS FOR OVERACTIVE BLADDER
PATIENTS ARE SATISFIED WITH TELEMEDICINE (HOME-CARE)
HEALTH RELATED QUALITY OF LIFE (HRQOL) IN CHRONIC DIALYSIS PATIENTS
PATIENTS TREATED WITH SERENOA REPENS
PATIENTS TREATED WITH SERENOA REPENS
BPH AND IPSS SCORES EVALUATED AFTER SIX MONTHS ACCORDING TO THE TYPE OF DISEASE MANAGEMENT
APPLYING CONJOINT ANALYSIS TO THE VALUATION OF OVERACTIVE BLADDER DRUGEFFICACY VARIABLES AND SIDE EFFECTS
REGIONAL SIMILARITIES IN IMPROVEMENT AND PERSISTENCE OF SHORT-TERM HEALTH-RELATED QUALITY OF LIFE EFFECT OF TOLTERODINE ON OVERACTIVE BLADDER PATIENTS
PREVALENCE OF APPROPRIATE URINARY INCONTINENCE EVALUATIONS IN TEXAS NURSING HOME FACILITIES
A SURVEY ON THE CLINICAL MANAGEMENT OF CMV RISK IN PATIENTS FOLLOWING RENAL TRANSPANTATION IN FRANCE
HEALTH CARE RESOURCE USE FOR HEAVY MENSTRUAL LOSS
COST ANALYSIS OF IVF TREATMENT WITH INJECTION DEVICE VS THE TRADITIONAL SYRINGE AND NEEDLE
SECOND-GENERATION VERSUS FIRST-GENERATION ENDOMETRIAL ABLATION TECHNIQUES IN THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING (DUB)
INFLUENCE OF ERECTILE DYSFUNCTION ON HEALTH RELATED QUALITY OF LIFE OF MALE KIDNEY TRANSPLANT PATIENTS ACCORDING TO AGE
PRELIMINARY VALIDATION OF A NEW DISEASE-SPECIFIC UTILITY MEASURE FOR ERECTILE DYSFUNCTION
POST-MENOPAUSAL HORMONE THERAPY
USING A DISCRETE CHOICE EXPERIMENT TO VALUE AN INJECTION DEVICE FOR INFERTILITY TREATMENT
ASSOCIATION BETWEEN PATERNAL EXPOSURE TO SOLVENTS AND SPONTANEOUS ABORTIONS
ASSOCIATION BETWEEN PATERNAL EXPOSURE TO SOLVENTS AND FETAL MALFORMATIONS
VITAMIN USE AMONG WOMEN OF CHILDBEARING AGE IN US